Arcturus Therapeutics Holdings/ARCT

$42.71

4.32%
-
1D1W1MYTD1YMAX

About Arcturus Therapeutics Holdings

Arcturus Therapeutics Holdings Inc. is a global late-stage clinical messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose level. It is leveraging its LUNAR platform and its nucleic acid technologies to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders with significant unmet medical needs. Its COVID-19 vaccine candidate, which is based on its STARR technology platform is through Phase II clinical trials.

Ticker

ARCT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Joseph Payne

Employees

170

Headquarters

San diego, United States

ARCT Metrics

BasicAdvanced
$999.99M
Market cap
11.30
P/E ratio
$3.31
EPS
2.63
Beta
-
Dividend rate

What the Analysts think about ARCT

Analyst Ratings

Majority rating from 10 analysts.
Buy

Price Targets

Average projection from 8 analysts.
52.77% upside
High $140.00
Low $18.00
$42.71
Current price
$65.25
Average price target

ARCT Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-35.92% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$45.1M
329.52%
Net income
$-16.2M
-69.14%
Profit margin
-35.92%
-92.82%

ARCT Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 63.94%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
$4.43
$1.87
-$1.98
-$0.61
-
Expected
$0.98
$0.06
-$0.21
-$1.69
-$0.99
Surprise
352.67%
3,029.71%
839.5%
-63.94%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Arcturus Therapeutics Holdings stock

Buy or sell Arcturus Therapeutics Holdings stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing